OnePin Peptide Library · Repair & Recovery
ARA-290
ARA290 · Cibinetide
ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the B helix of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heterodimer of the EPO receptor (EPOR) and the beta common receptor (CD131). Unlike EPO itself, ARA-290 does not stimulate erythropoiesis (red blood cell production) or affect hematocrit, which eliminates the thrombotic and cardiovascular risks associated with EPO use. ARA-290 promotes tissue repair, reduces inflammation, and provides neuroprotection through the IRR pathway, which is distinct from the classical EPO receptor responsible for erythropoiesis. It has been studied in Phase 2 clinical trials for diabetic neuropathy and sarcoidosis-related neuropathy.
Can be taken any time. No fasting required. 28-day cycle protocol.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
ARA-290 binds to and activates the innate repair receptor (IRR), which is a heterodimer of EPOR and CD131 (beta common receptor). This receptor is expressed on neurons, endothelial cells, and immune cells and is upregulated in response to tissue injury and inflammation. IRR activation triggers anti-apoptotic signaling (preventing cell death at injury sites), anti-inflammatory cytokine modulation, neural repair and remyelination signaling, endothelial protection and vascular repair, and macrophage phenotype switching from pro-inflammatory M1 to reparative M2. Critically, ARA-290 does NOT activate the classical EPOR homodimer responsible for erythropoiesis. This selectivity means ARA-290 provides tissue protective effects without increasing red blood cell production, hematocrit, or thrombotic risk.
ARA-290 binds to and activates the innate repair receptor (IRR), which is a heterodimer of EPOR and CD131 (beta common receptor). This receptor is expressed on neurons, endothelial cells, and immune cells and is upregulated in response to tissue injury and inflammation. IRR activation triggers anti-apoptotic signaling (preventing cell death at injury sites), anti-inflammatory cytokine modulation, neural repair and remyelination signaling, endothelial protection and vascular repair, and macrophage phenotype switching from pro-inflammatory M1 to reparative M2. Critically, ARA-290 does NOT activate the classical EPOR homodimer responsible for erythropoiesis. This selectivity means ARA-290 provides tissue protective effects without increasing red blood cell production, hematocrit, or thrombotic risk.
What to expect
Days 1-7: No significant changes expected. IRR activation initiates repair signaling but neural repair is a slow process.
Weeks 2-4: Neuropathic symptoms may begin to improve. Phase 2 trial showed measurable improvements at 28 days. Anti-inflammatory effects accumulate.
Weeks 4-12: Nerve fiber density improvements (measured by corneal confocal microscopy in clinical trials). Sustained tissue repair effects. Best assessed through symptom tracking and objective nerve function testing.
Evidence
The honest take
Non-erythropoietic tissue repair
Confirmed. ARA-290 selectively activates IRR without activating the classical EPO receptor. No effect on hematocrit or RBC production in clinical trials. This is its primary design advantage over EPO.
Phase 2 data shows objective nerve fiber density improvement (corneal confocal microscopy). Neuropathic pain reduction. The best-supported clinical claim for ARA-290.
Macrophage M1-to-M2 polarization documented. Distinct from classical anti-inflammatory pathways (NSAIDs, steroids). Complementary to other anti-inflammatory peptides.
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Side effects & safety
Commonly reported
- Well tolerated in clinical trials
- Mild injection site reaction
- Safety profile comparable to placebo in Phase 2 data
Less common & notes
- ARA-290 was specifically designed to avoid EPO-related risks (erythrocytosis, thrombosis, hypertension).
- Clinical trial safety data is favorable.
- No significant hematological changes observed.
- No significant cardiovascular events.
- Long-term data beyond 28 days is limited from controlled trials.
Pharmacokinetics
Storage. Store unreconstituted vials frozen (-20C) or refrigerated (2-8C). After reconstitution with BAC water, refrigerate at 2-8C. Stable for 28 days. Protect from light. EPO-derived structure but no special handling beyond standard peptide care.
Regulatory status
ARA-290 (Cibinetide) is an investigational drug. Phase 2 clinical trials completed by Araim Pharmaceuticals. Not yet approved by FDA or any regulatory agency. Available as a research peptide. WADA status: Not specifically listed but may fall under S0.
Put it to work
Calculate, log & track
Open ARA-290 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open ARA-290 in the app →Go deeper
The guide & community
The complete ARA-290 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗